<DOC>
	<DOC>NCT01992874</DOC>
	<brief_summary>This is a Phase 1, multi-center, open-label, single-dose, 2 period, 2 sequence cross-over trial to investigate the relative bioavailability of 2 solid oral pimasertib formulations in cancer subjects (Part A), followed by open-label pimasertib administration (Part B and trial extension phase).</brief_summary>
	<brief_title>Relative Bioavailability of Pimasertib in Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Pathologically confirmed solid tumors, either refractory to standard therapy or for which no effective standard therapy is available, with a measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 An Eastern Cooperative Oncology Group Performance Status (ECOG PS) of less than or equal to (&lt;=) 1 Other protocol defined inclusion criteria could apply Disease conditions or concomitant medication that may significantly influence the conduct of the trial or an abnormal electrocardiogram (ECG) or blood pressure at Screening as defined in the protocol Treatment with strong inhibitors or inducers of cytochrome P450 2C19 (CYP2C19) and CYP3A4 including fruit juices or beverages containing these substances History of prior mitogenactivated protein kinase/extracellular signalregulated kinase (MAPK/ERK) kinase (MEK) inhibitor exposure (including, pimasertib) or progression of disease on MEK inhibitors Evidence of a retinal vein occlusion (RVO) on fluorescein angiogram or a history of RVO Life expectancy of less than 12 weeks Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Pimasertib</keyword>
	<keyword>Cancer</keyword>
</DOC>